We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session

Upper GI (oesophagus, stomach, pancreas, liver)
Digital Poster
Clinical
Factors predicting pathological response after neoadjuvant chemoradiation in oesophageal cancer
Kundan Singh Chufal, India
PO-1205
SBRT in pancreatic cancer - a single institution experience
Ajra Secerov Ermenc, Slovenia
PO-1206
Stereotactic radiotherapy and MR-guided adaptive techniques for locally advanced pancreatic cancer
Tai Ermongkonchai, Australia
PO-1207
Stereotactic MR-guided online adaptive radiation therapy for management of pancreatic malignancies
Enis Ozyar, Turkey
PO-1208
SIB-SIP SBRT for locally advanced pancreatic cancer: clinical and dosimetric analysis.
Javier Peinado Serrano, Spain
PO-1209
Is SBRT safe in carcinoma pancreas having duodenal infiltration?
Reena Engineer, India
PO-1210
Intraluminal brachytherapy boost in esophageal cancer: A single institute retrospective analysis.
Nikhil Bathija, India
PO-1211
Outcome of adjuvant hypofractionated radiotherapy concomitant to chemotherapy in bile duct carcinoma
NAJLA SLIM, Italy
PO-1212
Radiomics in the assessment of response after pancreatic SBRT: a pilot study
CAROLINA DE LA PINTA, Spain
PO-1213
Toxicity profile of adjuvant hypofractionated Image-Guided Radiotherapy in biliary tract carcinoma
NAJLA SLIM, Italy
PO-1214
Indian experience of 100 HCC patients with portal vein thrombosis treated with robotic radiosurgery
Debnarayan Dutta, India
PO-1215
Outcomes and prognostic factors in neoadjuvant chemoradiotherapy for resectable esophageal cancer
Raquel Benlloch Rodriguez, Spain
PO-1216
Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma
Astrid Uttenthal Larsen, Denmark
PO-1217
Online adaptive MR-guided SBRT for unresectable upper abdominal malignancies using a 1.5T MR-linac
Lois Daamen, The Netherlands
PO-1218
Utility of MRI-guided adaptive radiotherapy for pancreatic cancer: Baskent University experience
Guler Yavas, Turkey
PO-1219
Prospective evaluation of Child Pugh score as a tool for assessment of acute toxicity in liver SBRT
Sreenija Yarlagadda, USA
PO-1220
Proton beam radiotherapy in pancreatic cancer: a systematic review
Letizia Cavallini, Italy
PO-1221
Robotic Stereotactic Radiosurgery for locally advanced pancreatic cancer-Local control and tolerance
Catarina Silva, Portugal
PO-1222
Prognostic factors affecting survival in gastric cancer patients in Albania: A retrospective study
Fatjona Kraja, Albania
PO-1223
SBRT as a part of the multimodal management of intermediate and advanced hepatocellular carcinoma
Ahmed Allam Mohamed, Germany
PO-1224
Hypofractionated radiotherapy after induction chemotherapy for advanced pancreatic cancer
Paolo Passoni, Italy
PO-1225
Inhomogeneous dose escalation in pancreatic SBRT:feasibility and impact of anatomical configuration
Mauro Loi, Italy
PO-1226
Impact of inflammation using blood parameters in HCC patients treated with SBRT
Gianluca Radicioni, Germany
PO-1227
STEREOTACTIC-BODY-RADIOTHERAPY (SBRT) AS RADIACL TREATMENT FOR PANCREATIC-NEUROENDOCRINE-TUMORS
Mercedes Lopez Gonzalez, Spain
PO-1228
ALBI & IBI score could help in deciding for or against a radioablative therapy in patients with HCC.
Peter Hass, Germany
PO-1229
18F-FDG PET-CT as prognosis factor after neoadjuvant chemoradiotherapy in esophageal cancer
Bruno Moura Fernandes, Portugal
PO-1230
Response to neoadjuvant RCT as a predictor for overall survival in therapy of esophageal cancer
Simon Kirste, Germany
PO-1231
Magnetic resonance-guided stereotactic body radiotherapy of liver tumors: Initial clinical experience and patient-reported outcomes
Fabian Weykamp, Germany
PO-1232
Real world results of CTRT in Ca esophagus: Can SCOPE-1 results be replicated outside trial setting?
Rohit Sasidharan, India
PO-1233
Chemoradiation in unresectable non metastatic biliary cancers: an updated systematic review
Silvia Bisello, Italy
PO-1234
Feasibility and early clinical experience of online adaptive MR-guided radiotherapy of liver tumors
Paul Rogowski, Germany
PO-1235
Stereotactic body radiotherapy in unresectable intrahepatic cholangio-carcinoma: a systematic review
Silvia Bisello, Italy
PO-1236
Dose-escalated neoadjuvant chemoradiotherapy for oesophageal or oesophagogastric junction carcinoma
VICTOR DUQUE-SANTANA, Spain
PO-1237
Volumetric modulated arc therapy is superior to intensity modulated radiotherapy for liver sparing in stereotactic body radiotherapy for hepatocellular carcinoma
Yulia Kundel, Israel
PO-1238
99mTc-macroaggregated albumin SPECT/CT in HCC treated with Selective Internal Radiation Therapy
Elisa Lodi Rizzini, Italy
PO-1239
Complete pathological response after high dose radiotherapy for locally advanced esophageal cancer.
Ovidio Hernando-Requejo, Spain
PO-1240
Optimising splenic dose with PBT and VMAT for distal oesophageal cancer
Owen Nicholas, United Kingdom
PO-1241